Antares Pharma Inc. ATRS was a big mover last session, as the company saw its shares rise more than 10% on the day. Shares moved up after the company along with Teva Pharmaceutical Industries Ltd announced the launch of the generic equivalent to Imitrex (sumatriptan succinate) injection, 4 mg and 6 mg single-dose, prefilled syringe autoinjectors, in the U.S. This led to solid volume too with far more shares changing hands than in a normal session. This stock, trading in a volatile price range of $0.95–$1.17 in the past one-month time frame, showed a pick-up yesterday at $1.05.
None of the estimates for this Med/Dental-Supplies industry stock were revised over the past 30 days. However, the Zacks Consensus Estimate moved down over the same time frame, signaling trouble down the road. So make sure to keep an eye on this stock going forward to see if yesterday’s move higher lasts.
Antares Pharma has a Zacks Rank #4 (Sell), while its Earnings ESP is 0.00%.
However, a better-ranked stock in the same space is Halyard Health, Inc. HYH, sporting a Zacks Rank #1 (Strong Buy).
Is ATRS going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment